The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial.
BegoƱa Bermejo
No relevant relationships to disclose
Amparo Ruiz
No relevant relationships to disclose
Manuel Ruiz Borrego
No relevant relationships to disclose
Nuria Ribelles
No relevant relationships to disclose
Alvaro Rodriguez-Lescure
Consultant or Advisory Role - Roche
Honoraria - Roche
Montserrat Munoz-Mateu
No relevant relationships to disclose
Sonia Gonzalez
No relevant relationships to disclose
Mireia Margeli
No relevant relationships to disclose
Agust Barnadas
No relevant relationships to disclose
Manuel Ramos Vazquez
No relevant relationships to disclose
Sonia del Barco
No relevant relationships to disclose
Lourdes Calvo
No relevant relationships to disclose
Cesar Mendiola
No relevant relationships to disclose
Carmen Crespo
No relevant relationships to disclose
Cesar Augusto Rodriguez
No relevant relationships to disclose
Eduardo Martinez
No relevant relationships to disclose
Maria Isabel Casas
No relevant relationships to disclose
M Carmen Camara
No relevant relationships to disclose
Eva Maria Carrasco
No relevant relationships to disclose
Miguel Martin
Consultant or Advisory Role - Amgen; Roche